These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 11956430)

  • 1. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
    Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
    J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml.
    Okihara K; Fritsche HA; Ayala A; Johnston DA; Allard WJ; Babaian RJ
    J Urol; 2001 Jun; 165(6 Pt 1):1930-6. PubMed ID: 11371884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ
    J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer.
    Mitchell ID; Croal BL; Dickie A; Cohen NP; Ross I
    J Urol; 2001 May; 165(5):1549-53. PubMed ID: 11342915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
    J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report.
    Babaian RJ; Fritsche HA; Zhang Z; Zhang KH; Madyastha KR; Barnhill SD
    Urology; 1998 Jan; 51(1):132-6. PubMed ID: 9457308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
    Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
    BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
    Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
    Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer.
    Martínez M; España F; Royo M; Vera CD; Estellés A; Jiménez-Cruz JF; Medina P; Aznar J
    Eur Urol; 2000 Jul; 38(1):85-90. PubMed ID: 10859447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
    Letran JL; Blase AB; Loberiza FR; Meyer GE; Ransom SD; Brawer MK
    J Urol; 1998 Aug; 160(2):426-9. PubMed ID: 9679891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume.
    Stamey TA; Yemoto CE
    J Urol; 2000 Jan; 163(1):119-26. PubMed ID: 10604328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complexed prostate-specific antigen for the detection of prostate cancer.
    Filella X; Truan D; Alcover J; Gutierrez R; Molina R; Coca F; Ballesta AM
    Anticancer Res; 2004; 24(6):4181-5. PubMed ID: 15736470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
    Saika T; Tsushima T; Nasu Y; Kusaka N; Miyaji Y; Takamoto H; Takeda K; Uno S; Kumon H;
    Cancer; 2002 Mar; 94(6):1685-91. PubMed ID: 11920529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia .
    Filella X; Alcover J; Molina R; Corral JM; Carretero P; Ballesta AM
    Prostate; 2000 Feb; 42(3):181-5. PubMed ID: 10639188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.